The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.
The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis.
复制标题
阿苯达唑治疗对有症状的神经囊尾蚴病患者非癫痫发作结果的影响。
DOI：
10.1093/trstmh/try023
复制
发表时间：
2018
影响因子：
2.2
通讯作者：
Kelvin,ElizabethA
中科院分区：
文献类型：
--
作者：
Thapa,Kriti;Romo,MatthewL;Carpio,Arturo;Leslie,Denise;Andrews,Howard;Hauser,WAllen;Kelvin,ElizabethA
背景关于驱虫治疗对脑囊虫病（NC）患者除癫痫发作外的临床症状的影响，目前还缺乏相关信息。我们调查了阿苯达唑对非癫痫发作症状的患者所经历的NC。MethodsData是从一个随机对照试验比较阿苯达唑加泼尼松与安慰剂加泼尼松治疗NC之间的活动或过渡NC囊肿和新发症状173例。我们进行负二项回归检查的后续访问的数量时，症状报告，逻辑回归检查的概率经历的症状和考克斯比例风险模型检查的时间首次报告symptoms.Results85%的患者报告至少有一个非癫痫发作的症状在基线。接受阿苯达唑治疗的患者在1-24个月期间记忆丧失和/或意识模糊的几率显著降低（比值比[OR] 0.42，p=0.037），在1-12个月期间焦虑和/或抑郁的几率显著增加（OR 1.87，p=0.049）。没有治疗差异存在于经历的症状一般或在经历头痛，四肢无力或步态障碍，呕吐，恶心和/或胃痛或视力障碍的后续periods.ConclusionsWhile非癫痫发作症状的患病率高，阿苯达唑治疗与随访的非癫痫发作症状只有两个显着差异。需要进一步的研究来确定减少NC患者长期症状负担的策略。
BackgroundThere is little information about the impact of anthelminthic treatment on clinical symptoms other than seizures in neurocysticercosis (NC). We investigated the effect of albendazole on non-seizure symptoms experienced by patients with NC.MethodsData are from a randomized controlled trial comparing albendazole plus prednisone with placebo plus prednisone for treatment of NC among 173 patients with active or transitional NC cysts and new-onset symptoms. We performed negative binomial regression to examine the number of follow-up visits when a symptom was reported, logistic regression to examine the probability of experiencing the symptom and Cox proportional hazards models to examine the time to first reporting the symptom.ResultsEighty-five percent of patients reported at least one non-seizure symptom at baseline. Those treated with albendazole had significantly lower odds of memory loss and/or confusion during months 1–24 (odds ratio [OR] 0.42, p=0.037) and significantly increased odds of anxiety and/or depression during months 1–12 (OR 1.87, p=0.049). No treatment difference existed in experiencing symptoms in general or in experiencing headaches, limb weakness or gait disturbances, vomiting, nausea and/or stomach pain or visual disturbances over the follow-up period.ConclusionsWhile the prevalence of non-seizure symptoms was high, albendazole treatment was associated with only two significant differences in the non-seizure symptoms over follow-up. Further research is needed to identify strategies to reduce the long-term symptom burden in patients with NC.